GROWING GLOBALLY
From its inception, Biopharma has been trying to transform its local endeavor into an international arena to achieve the trust and confidence of healthcare professionals and patients across the globe. It has become one of the leading exporters of pharmaceutical finished products in Bangladesh within a couple of years after stepping beyond the native market. In the age of globalization, the world has no boundaries. To cope with the challenges of globalization, Biopharma Limited began export operations in 2006. Currently, we are exporting a wide range of pharmaceutical products under different therapeutic categories. Biopharma Limited has a portfolio comprising antiulcerants, antibiotics, NSAIDs, antipyretics, vitamins and minerals, cardiovascular, anti-diabetics, antihistamines, antipsychotics, etc. Biopharma Limited always thrives on introducing hi-tech & innovative dosage forms for the betterment of our patients. Its state-of-the-art facility is planned and designed with fine-tuned orientation to meet both local and international demands. Biopharma continuously sets higher standards and has the passion to achieve it all. WHO-approved cGMP guidelines are strictly followed at every step during production. Every member of the company is working persistently to uphold quality.
Business association with Biopharma Limited will ensure the availability of new products at reasonable prices along with generic products. It will ensure a win-win situation between the companies and countries. Biopharma Limited, from the very beginning, has objectives to contribute to the global health sector by providing Quality health products of international standards. We offer the best services regarding manufacturing facilities, product development, and quality. Within a very short period, Biopharma Limited received very positive responses from different countries of the world.
Biopharma Manufactures Bioequivalent Products
To expedite its export mission, Biopharma Limited conducted bioequivalence studies on a variety of its products. The regulatory bodies of several countries have already accepted these bioequivalence reports and, thus, are helping export. Recently, six products have undergone a Bioequivalence (BE) Study in US-FDA approved, renowned Contract Research Organization (CRO) and compared with innovative company's products. These are studies have shown and proven that Biopharma's Products meet Pharmaceutical and Pharmacological parameters and Bioequivalent to the Originator Brands.
- Maczith 500 Tablet (Azithromycin) is equivalent to Zithromax 500 (Pfizer)
- Mextil 500 Tablet (Cefuroxime) is equivalent to Zinace 500 (GlaxoSmithKline)
- Mextil Powder for Suspension (Cefuroxime) is equivalent to Zinnat Powder for Suspension (GlaxoSmithKline)
- Bestcef 200 Capsule (Cefixime) is equivalent to Tergecef 200 (Unilab)
- Bestcef Powder for Suspension (Cefixime) is equivalent to Tergecef Powder for Suspension (Unilab)
- Inpro 40 Capsule (Omeprazole) is equivalent to Losec 40 (AstraZeneca)
